These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 10170453)

  • 41. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
    Heuzenroeder L; Donnelly M; Haby MM; Mihalopoulos C; Rossell R; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):602-12. PubMed ID: 15298582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
    Smith D; Dempster C; Glanville J; Freemantle N; Anderson I
    Br J Psychiatry; 2002 May; 180():396-404. PubMed ID: 11983635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing depressive and anxiety disorders with escitalopram.
    Thase ME
    Expert Opin Pharmacother; 2006 Mar; 7(4):429-40. PubMed ID: 16503815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.
    Gartlehner G; Hansen RA; Carey TS; Lohr KN; Gaynes BN; Randolph LC
    Int Clin Psychopharmacol; 2005 Mar; 20(2):59-69. PubMed ID: 15729080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical evaluation of venlafaxine.
    Ballenger JC
    J Clin Psychopharmacol; 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S. PubMed ID: 8784646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Venlafaxine: a novel antidepressant that has a dual mechanism of action.
    Andrews JM; Ninan PT; Nemeroff CB
    Depression; 1996; 4(2):48-56. PubMed ID: 9160640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paroxetine. A pharmacoeconomic evaluation of its use in depression.
    Wilde MI; Whittington R
    Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Venlafaxine versus sertraline for major depressive disorder.
    Wise TN; Sheridan MJ
    J Clin Psychiatry; 2000 Nov; 61(11):873-4. PubMed ID: 11105744
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.
    van den Broek WW; Mulder PG; van Os E; Birkenhäger TK; Pluijms E; Bruijn JA
    J Psychopharmacol; 2009 Aug; 23(6):708-13. PubMed ID: 18562424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
    Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
    Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of newer antidepressants for panic disorder.
    Gorman JM
    J Clin Psychiatry; 1997; 58 Suppl 14():54-8; discussion 59. PubMed ID: 9418747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
    Augustin BG; Cold JA; Jann MW
    Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.